Apogee Therapeutics (APGE) Shares Outstanding (Weighted Average) (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Shares Outstanding (Weighted Average) data on file, last reported at $69.7 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 19.71% year-over-year to $69.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.7 million (up 19.71% YoY) and the FY2025 annual result came in at $60.7 million, up 9.96% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $69.7 million in Q1 2026 per APGE's latest filing, from $60.7 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $69.7 million in Q1 2026 and bottomed at $1.2 million in Q2 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $52.3 million (2024), against an average of $37.7 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) surged 2618.43%; it then rose 3.18% in 2025.
• Tracing APGE's Shares Outstanding (Weighted Average) over 5 years: stood at $2.5 million in 2022, then surged by 915.57% to $25.0 million in 2023, then soared by 120.72% to $55.2 million in 2024, then increased by 9.96% to $60.7 million in 2025, then advanced by 14.79% to $69.7 million in 2026.
• Per Business Quant, the three latest APGE Shares Outstanding (Weighted Average) figures stand at $69.7 million (Q1 2026), $60.7 million (Q4 2025), and $58.8 million (Q3 2025).

Peer Comparison